Pfizer Stock Poised for Healthy Gains

The drug maker's cancer-fighting unit helped lift quarterly results. With a 3.1% yield, the stock looks cheap even after its recent run.

Pfizer is losing patents on some drugs, but it found a way to post another good quarter.

The company reported third-quarter earnings early Tuesday of 58 cents per share, two cents better than the median among analysts surveyed, according to Thomson Reuters I/B/E/S. Earnings benefited from reduced operating costs and a lower tax rate.